期刊文献+

西妥昔单抗联合调强放疗及TP方案化疗治疗局部晚期鼻咽癌初步研究 被引量:5

Preliminary Results of Cetuximab Combined with Intensitymodulated Radiotherapy(IMRT) and TP Regimen Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma
原文传递
导出
摘要 [目的]研究西妥昔单抗联合调强放疗及TP方案化疗治疗局部晚期鼻咽癌的近期疗效及不良反应。[方法]21例局部区域晚期鼻咽癌患者接受调强放射治疗及TP方案同步化疗2个周期,同时接受每周1次的西妥昔单抗治疗。采用CTCAE3.0记录治疗期间的最大不良反应;观察局部区域控制及远处转移情况。[结果]21例患者都完成预定调强放射治疗计划,20例(95.2%)患者完成了预定的西妥昔单抗治疗,19例(90.5%)患者完成了2个周期的TP方案化疗。无治疗相关性死亡发生,4级不良反应包括白细胞减少(7例,33.4%),中性粒细胞减少(3例,14.3%),血小板减少(1例,4.8%)及4级唑疮样皮疹(1例,4.8%)。口腔及口咽黏膜炎、骨髓抑制、放射性皮炎、呕吐为常见的3级毒性。中位随访13个月,21例患者1年局部控制率、区域控制率及无远处转移生存率为100.0%、100.0%及95.2%。[结论]西妥昔单抗联合调强放疗及TP方案化疗治疗局部晚期鼻咽癌近期疗效令人鼓舞,不良反应可控可逆。 [Purpose] To investigate the short term response and toxicity of cetuximab combined with intensity-modulated radiotherapy (IMRT) and TP regimen chemotherapy for locally ad- vanced nasopharyngeal carcinoma (NPC). [Methods] Twenty-one cases with locally advanced NPC were treated with IMRT,two cycles of concurrent TP regimen chemotherapy, and cetuximab weekly. The severest acute toxicities were recorded according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, and the local control and distance metastasis were ob- served. [Results] All the 21 patients finished planned radiation dose,20 patients (95.2%) fin- ished planned cetuximab therapy, 19 patients (90.5%) finished planned two cycles of TP regi- men chemotherapy. No treatment related death happened. Grade 4 toxicities included leukope- nia(7 cases, 33.4%),neutropenia (3 cases, 14.3%),thrombocytopenia (1 case,4.8%),acneiform rash grade 4 (1 case ,4.8%). Oral and oropharyngeal mncositis, marrow depression, radiotherapy induced dermatitis,and vomitting were common toxicity with grade 3. With a median follow-up of 13 months,the local,regional,and distant control rate for the 21 cases were 100.0%, 100.0% and 95.2% respectively. [Conclusion] Cetuximab in combination with IMRT and TP regimen chemotherapy is a feasible strategy against locally advanced NPC with controllable and re- versible toxicities.
机构地区 江苏省肿瘤医院
出处 《肿瘤学杂志》 CAS 2012年第12期923-926,共4页 Journal of Chinese Oncology
关键词 西妥昔单抗 鼻咽肿瘤 调强放疗 同步放化疗 cetuximab nasopharyngeal neoplasms intensity-modulated radiotherapy (IM-RT) concurrent radiochemotherapy
  • 相关文献

参考文献12

  • 1Wee J,Tan EH,Tai BC. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer stage Ⅲ and Ⅳ nasopharyngeal cancer of the endemic variety[J].Journal of Clinical Oncology,2005,(27):6730-6738.doi:10.1200/JCO.2005.16.790.
  • 2Airoldi M,Gabriele AM,Garzaro M. Induction chemotherapy with cisplatin and epirubicin followed by radiotherapy and concurrent cisplatin in locally advanced nasopharyngeal carcinoma observed in a non-endemic population[J].Radiotherapy and Oncology,2009,(01):105-110.doi:10.1016/j.radonc.2009.02.005.
  • 3赵充,卢泰祥.鼻咽癌放射治疗技术规范浅析[J].肿瘤学杂志,2009,15(7):609-612. 被引量:2
  • 4Fukuda M,Shinkai T,Eguchi K. Phase Ⅱ study of (glycolate-O,O') diammineplatinum(Ⅱ),a novel platinum complex,in the treatment of non-small-cell lung cancer[J].Cancer Chemotherapy and Pharmacology,1990,(06):393-396.
  • 5Nakamura T,Kodaira T,Tachibana H. Chemoradiotherapy for locally recurrent nasopharyngeal carcinoma:treatment outcome and prognostic factors[J].Japanese Journal of Clinical Oncology,2008,(12):803-809.
  • 6Burtness B,Goldwasser MA,Flood W. Eastern Cooperative Oncology Group.Phase Ⅲ randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer:an Eastern Cooperative Oncology Group study[J].Journal of Clinical Oncology,2005,(34):8646-8654.doi:10.1200/JCO.2005.02.4646.
  • 7Ma BB,Kam MK,Leung SF. A phase Ⅲ study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma[J].Annals of Oncology,2012,(05):1287-1292.
  • 8Ma BB,Poon TC,To KF. Expression and prognostic significance of epidermal growth factor receptor and HER2 protein in nasopharyngeal carcinoma[J].Head & Neck,2003,(10):864-872.
  • 9Chan AT,Hsu MM,Goh BC. Multicenter,phase Ⅱ study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma[J].Journal of Clinical Oncology,2005,(15):3568-3576.
  • 10Li GH,Zhu B,Yang F. Use of cetuximab in combination with pulsed reduced dose-rate radiotherapy in a patient with recurrence of nasopharyngeal carcinoma in the neck[J].Exp Ther Med,2012,(05):869-872.

二级参考文献17

共引文献1

同被引文献43

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部